Department of Paediatric Dermatology, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany.
Clin Exp Dermatol. 2021 Apr;46(3):495-502. doi: 10.1111/ced.14513. Epub 2020 Dec 25.
Vascular malformations (VMs) are caused by localized defects of vascular development. Most VMs are due to sporadic, postzygotic mutations, while some are the result of autosomal dominant germline mutations. Genotype-phenotype correlation is influenced by many factors. Individual genes can induce different phenotypes (pleiotropy), and similar phenotypes can be due to different genes/mutations (redundancy). The phenotypic spectrum of somatic mutations is wide, and depends on variant allele frequency, timing during embryogenesis, cell type(s) involved and type of mutation. The phenotype of germline mutations is determined by penetrance and expressivity, and is influenced by epigenetic factors (DNA methylation, histone modification) or 'second-hit' somatic mutations. Except for disorders with pathognomonic phenotypes such as Proteus syndrome or a characteristic constellation of symptoms such as CLOVES [congenital lipomatous (fatty) overgrowth, vascular malformations, epidermal naevi and scoliosis/skeletal/spinal anomalies] or PIK3CA-related overgrowth spectrum syndrome, differential diagnosis of VM is therefore difficult. It will be greatly facilitated with increasing analytic sensitivity of sequencing techniques such as next-generation sequencing. High-sensitivity molecular techniques are a prerequisite for targeted pharmacotherapy, i.e. selective therapeutic inhibition of activating mutations underlying VM, which has shown promising results in preliminary studies.
血管畸形(VMs)是由血管发育的局部缺陷引起的。大多数 VMs 是由于散发性、合子后突变引起的,而有些则是常染色体显性种系突变的结果。基因型-表型相关性受多种因素影响。个别基因可诱导不同的表型(多效性),而相似的表型可能是由于不同的基因/突变(冗余)引起的。体细胞突变的表型谱很广,取决于变异等位基因频率、胚胎发生过程中的时间、涉及的细胞类型和突变类型。种系突变的表型由外显率和表现度决定,并受表观遗传因素(DNA 甲基化、组蛋白修饰)或“二次打击”体细胞突变的影响。除了具有特征性表型的疾病,如 Proteus 综合征或具有特征性症状组合的疾病,如 CLOVES[先天性脂肪(脂肪)过度生长、血管畸形、表皮痣和脊柱侧凸/骨骼/脊柱异常]或 PIK3CA 相关过度生长谱综合征外,VM 的鉴别诊断因此非常困难。随着下一代测序等分析敏感性不断提高的测序技术的出现,这将变得更加容易。高灵敏度分子技术是靶向药物治疗的前提,即选择性治疗抑制 VM 潜在的激活突变,这在初步研究中已经显示出了良好的效果。